Exclusive interview with Alex Zhavoronkov
Insilico CEO on spreading the longevity message – the time is now. Dr Alex Zhavoronkov is the CEO and co-founder …
Continue reading “Exclusive interview with Alex Zhavoronkov”
Insilico’s Dr Alex Zhavoronkov defines Longevity
The “MMA fighter” of Longevity talks business models, AI drug discovery and working with the right investors. Dr Alex Zhavoronkov …
Continue reading “Insilico’s Dr Alex Zhavoronkov defines Longevity”
Insilico appoints co-CEO in readiness for clinical data test
Dr Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is set to leverage his GSK …
Continue reading “Insilico appoints co-CEO in readiness for clinical data test”
Insilico raise $60 million and launch AI-powered drug discovery robotics laboratory
Insilico Medicine’s $60 million Series D financing raise will see the AI-driven drug discovery company advance its pipeline. Insilico Medicine, …
Longevity takes over Davos – and has Gstaad in its sights
Longevity was one of the most talked about industries on the streets of Davos during this year’s World Economic Forum …
Continue reading “Longevity takes over Davos – and has Gstaad in its sights”
9th ARDD packed with more than 70 leaders in aging and longevity
Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of …
Continue reading “9th ARDD packed with more than 70 leaders in aging and longevity”
Deep Longevity – extending longevity and increasing human performance
Deep Longevity – on a mission to extend healthy productive longevity and increase human performance. Over the coming weeks, we …
Continue reading “Deep Longevity – extending longevity and increasing human performance”
Insilico identifies therapeutic targets implicated in aging using AI and hallmarks of aging framework
Identifying dual-purpose therapeutic targets that are implicated in aging and disease will extend healthspan and delay age-related health issues. Insilico …
Insilico announces strategic collaboration for AI-driven drug discovery
New collaboration leverages Insilico’s end-to-end discovery platform and EQRx’s innovative business model to accelerate drug development. Insilico Medicine has announced …
Continue reading “Insilico announces strategic collaboration for AI-driven drug discovery”
